In last trading session, Mereo BioPharma Group plc (NASDAQ:MREO) saw 1,218,455 shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $3.33 trading at -$0.13 or -3.76% at ring of the bell on the day assigns it a market valuation of $374.53 Million. That closing price of MREO’s stock is at a discount of -41.47% from its 52-week high price of $4.711 and is indicating a premium of 69.37% from its 52-week low price of $1.02. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 2.9 Million shares which gives us an average trading volume of 2.5 Million if we extend that period to 3-months.
For Mereo BioPharma Group plc (MREO), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.5. Splitting up the data highlights that, out of 2 analysts covering the stock, none rated the stock as a Sell while none recommended an Overweight rating for the stock. None suggested the stock as a Hold whereas 2 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.
Mereo BioPharma Group plc (NASDAQ:MREO) trade information
In the face of being in the red during last session for losing -3.76%, in the last five days MREO remained trading in the green while hitting it’s week-highest on Friday, Apr 09 when the stock touched $4.29-2 price level, adding 22.41% to its value on the day. Mereo BioPharma Group plc’s shares saw a change of -6.98% in year-to-date performance and have moved -17.37% in past 5-day. Mereo BioPharma Group plc (NASDAQ:MREO) showed a performance of -19.57% in past 30-days. Number of shares sold short was 8.22 Million shares which calculate 3.29 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $5.28 to the stock, which implies a rise of 58.56% to its current value. Analysts have been projecting $0.55 as a low price target for the stock while placing it at a high target of $10. It follows that stock’s current price would jump +200.3% in reaching the projected high whereas dropping to the targeted low would mean a loss of -83.48% for stock’s current value.
Mereo BioPharma Group plc (MREO) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2021, company’s earnings growth rate is likely to be around 0% while estimates for its earnings growth in next 5 years are of 0%
Mereo BioPharma Group plc (NASDAQ:MREO)’s Major holders
Insiders are in possession of 0.24% of company’s total shares while institution are holding 62.52% percent of that, with stock having share float percentage of 62.67%. Investors also watch the number of corporate investors in a company very closely, which is 50 institutions for Mereo BioPharma Group plc that are currently holding shares of the company. Orbimed Advisors LLC. is the top institutional holder at MREO for having 13.82 Million shares of worth $49.46 Million. And as of December 30, 2020, it was holding 12.76% of the company’s outstanding shares.
The second largest institutional holder is Boxer Capital, LLC, which was holding about 6.23 Million shares on December 30, 2020. The number of shares represents firm’s hold over 5.75% of outstanding shares, having a total worth of $22.29 Million.
On the other hand, Primecap Odyssey Aggressive Growth Fund and Fidelity NASDAQ Composite Index Fund are the top two Mutual Funds which own company’s shares. As of January 30, 2021, the former fund manager was holding 385100 shares of worth $1.05 Million or 0.36% of the total outstanding shares. The later fund manager was in possession of 8.46 Thousand shares on February 27, 2021, making its stake of worth around $32.89 Thousand in the company or a holder of 0.01% of company’s stock.